Aim. Pseudomyxoma peritonei PMP is a rare form of peritoneal carcinomatosis characterized by abnormal quantity of extracellular mucinous material. It almost originates from a primary appendiceal tumor with different malignancy degrees. The purpose of this study was to evaluate outcome and longterm survival on 80 patients affected by PMP after cytoreductive surgery CRS associated with hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. From October 1995 to June 2012, about 550 operations for PC were performed; in 300 cases surgical cytoreduction in association with HIPEC was carried out. Regarding PMP, 80 procedures of CRS and HIPEC were performed. This approach is based on surgical removal of the primitive cancer, peri-tonectomy (stripping of implants on the peri-toneal surface) and HIPEC performed with cisplatinum and C mytomicin. The rationale of this treatment is to obtain, after macroscopic disease removal, an elevated and persistent drug concentration in the peritoneal cavity, with limited systemic effects. Results. The complication rate was 52.5% (42/80) with no postoperative deaths. The median overall and progression-free survival were 144 and 88 months, respectively. Not complete cytoreductive surgery (P
|Number of pages||9|
|Publication status||Published - Dec 2013|
- Malignant hyperthermia.
- Pseudomyxoma peritonei
ASJC Scopus subject areas